PRTA
NASD Prothena Corp. Plc$8.53 ↑ +0.15 (+1.79%) Trading Up from the previous close of $8.38, $0.46 below the day’s high of $8.99
- YTD change
- -10.68%
- vs 20-day SMA
- -4.30%
- vs 200-day SMA
- -8.75%
Price ranges
Price & Performance
-0.47 (-5.08%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 89.3% away from all-time highs of $79.75
- PRTA is down 11% since the beginning of the year
- PRTA is down 13% over the past 12 months
- PRTA is down 9% over the past 1 month
- 19% of all PRTA investors are betting against PRTA
PRTA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -10.0%.
- Previous minute
- +$0.00
- Last hour
- +$0.15
- Last 5 days
- -5.12%
- vs 8-day SMA
- -0.91%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
